Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Regenxbio Inc

RGNX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$10.77

▲ +0.98%

Market Cap $710.63M · Vol 279.56K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$710.63M

Small Cap

Div Yield

N/A

EPS Growth

+20.69%

YoY

RSI (14)

62.11

Momentum

Beta

0.96

vs Market

52W High

$16.19

33.51% below

52W Low

$5.46

97.16% above

Volume

279.56K

Avg 554.87K

P/B

7.13

Price-to-book

ROE

-107.00%

Return on equity

Free Float

92.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Regenxbio Inc (RGNX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RGNX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.42%

-12.41%

+72.38%

+34.73%

YTD

-25.24%

+18.82%

-40.29%

-65.75%

Financials & Valuation

TTM · Annual

Total Revenue	$170.44M
Net Income	$-193,878,000.00
Revenue Growth (YoY)	+405.73%
Gross Margin	88.09%
Operating Margin	-94.52%
Net Profit Margin	-113.75%
ROE	-107.00%
ROA · ROIC	-42.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.36
P/B	7.13
P/FCF	N/A
EPS Growth	+20.69%
Outstanding Shares	66.01M

Technical Indicators

50-Day SMA	$10.26
200-Day SMA	$10.47
RSI (14)	62.11
Beta	0.96
52-Week High	$16.19
52-Week Low	$5.46

Volume Today	279.56K
Avg Daily Volume (30D)	554.87K
Relative Volume	0.50x
Volatility (10D)	53.32
Volatility (30D)	81.69
Free Float	92.92%

Analyst Consensus

BUY

Current Price $10.77

Mean Target $26.25

52W Low$5.46 52W High$16.19

Current

Target

$5.46 $16.19

Current Analyst target

+143.85% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007Z9V5C7

ISINUS75901B1070

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.